Pharmaceuticals, Biotechnology and Life Sciences
Acquisition strengthens Lyell’s clinical pipeline with the addition of IMPT-314, a dual-targeting CD19/CD20 CAR T-cell product candidate expected to initiate…
WATERTOWN, Mass., Oct. 31, 2024 (GLOBE NEWSWIRE) — EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing…
WOBURN, Mass., Oct. 31, 2024 (GLOBE NEWSWIRE) — iSpecimen Inc. (Nasdaq: ISPC) (“iSpecimen” or the “Company”), an online global marketplace that…
Photo caption: Rwanda Minister of State for Health, Yvan Butera, was among those who received Sabin’s investigational vaccine in the…
Includes initial funding of approximately $5 million, as well as the option for additional proceeds of approximately $5 millionNEW YORK,…
-New testing method highlights link between protofibrils and biomarkers for neurodegeneration–Patient and caregiver perspectives on five-year treatment with lecanemab —…
NEW YORK, Oct. 30, 2024 (GLOBE NEWSWIRE) — Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory…
PRINCETON, N.J., Oct. 30, 2024 (GLOBE NEWSWIRE) — ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (NASDAQ: ANIP) today announced that…
SUNNYVALE, Calif., Oct. 30, 2024 (GLOBE NEWSWIRE) — 23andMe Holding Co. (Nasdaq: ME) (the “Company” or “23andMe”), a leading human…
WVE-007 (INHBE GalNAc-siRNA for obesity) is on track to initiate a clinical trial in 1Q 2025; new preclinical data for…